Molecular pathogenesis of cholangiocarcinoma

Digestive Diseases

Volumn 32, Issue 5, 2014, Pages 564-569

  Rizvi, Sumera ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer associated fibroblast; Cholangiocarcinoma; Inflammation; Tumor microenvironment

Indexed keywords

ANGIOGENESIS; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CELL PROLIFERATION; DNA DAMAGE; EPIGENETICS; FIBROBLAST; GENE MUTATION; HUMAN; INFLAMMATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK FACTOR; STROMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION; ANIMAL; BILE DUCT TUMOR; GENETIC EPIGENESIS; GENETICS; INTRAHEPATIC BILE DUCT; PATHOLOGY; BILIARY TRACT INFLAMMATION; CANCER ASSOCIATED FIBROBLAST; CHRONIC INFLAMMATION; CONFERENCE PAPER; ENZYME INHIBITION; EXPERIMENTAL MODEL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DNA DAMAGE; EPIGENESIS, GENETIC; FIBROBLASTS; HUMANS;

CYTOKINE; GROWTH FACTOR RECEPTOR;

EID: 84904612083     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000360502     Document Type: Article

References (44)

1. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
2. Spechler SJ: Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310: 627-636.
3. Yadav D, Lowenfels AB: The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013; 144: 1252-1261.
4. Wilson KT, Crabtree JE: Immunology of Helicobacter pylori : insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007; 133: 288-308.
5. Ullman TA, Itzkowitz SH: Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-1816.
6. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 184-190.
7. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ: Interleukin-6 contributes to Mcl-1 up-regulation and trail resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005; 128: 2054-2065.
8. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004; 41: 808-814.
9. Lai GH, Radaeva S, Nakamura T, Sirica AE: Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated 'intestinal-type' biliary cancer chemically induced in rat liver. Hepatology 2000; 31: 1257-1265.
10. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ: Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002; 122: 985-993.
11. Yoon JH, Canbay AE, Werneburg NW, Lee SP, Gores GJ: Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology 2004; 39: 732-738.
12. Razumilava N, Gores GJ: Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 2013; 11: 13- 21.e11; quiz e13-e14.
13. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM: Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals two classes that have different outcomes. Gastroenterology 2013; 144: 829-840.
14. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000; 100: 57-70.
15. Sia D, Tovar V, Moeini A, Llovet JM: Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013; 32: 4861-4870.
16. Jaiswal M, LaRusso NF, Shapiro RA, Billiar TR, Gores GJ: Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001; 120: 190-199.
17. Kuver R: Mechanisms of oxysterol-induced disease: insights from the biliary system. Clin Lipidol 2012; 7: 537-548.
18. Haigh WG, Lee SP: Identification of oxysterols in human bile and pigment gallstones. Gastroenterology 2001; 121: 118-123.
19. Nachtergaele S, Mydock LK, Krishnan K, Rammohan J, Schlesinger PH, Covey DF, Rohatgi R: Oxysterols are allosteric activators of the oncoprotein smoothened. Nat Chem Biol 2012; 8: 211-220.
20. Corcoran RB, Scott MP: Oxysterols stimulate sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proc Natl Acad Sci USA 2006; 103: 8408-8413.
21. Dwyer JR, Sever N, Carlson M, Nelson SF, Beachy PA, Parhami F: Oxysterols are novel activators of the hedgehog signaling pathway in pluripotent mesenchymal cells. J Biol Chem 2007; 282: 8959-8968.
22. Nedelcu D, Liu J, Xu Y, Jao C, Salic A: Oxysterol binding to the extracellular domain of smoothened in hedgehog signaling. Nat Chem Biol 2013; 9: 557-564.
23. Andersen JB, Thorgeirsson SS: Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2012; 28: 266-272.
24. Ahrendt SA, Eisenberger CF, Yip L, Rashid A, Chow JT, Pitt HA, Sidransky D: Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res 1999; 84: 88-93.
25. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ, Halling KC: Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 2012; 43: 1552-1558.
26. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY: Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013; 32: 3091-3100.
27. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17: 72-79.
28. Reitman ZJ, Parsons DW, Yan H: IDH1 and IDH2: Not your typical oncogenes. Cancer Cell 2010; 17: 215-216.
29. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-630.
30. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, Yen KE: Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340: 622-626.
31. Cheon YK, Cho YD, Moon JH, Jang JY, Kim YS, Lee MS, Lee JS, Shim CS: Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007; 102: 2164-2170.
32. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 142: 1021-1031 e1015.
33. Schafer ZT, Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest 2007; 117: 3660-3663.
34. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR: Gp130-mediated STAT3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
35. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ: Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007; 132: 384-396.
36. Zender S, Nickeleit I, Wuestefeld T, Sorensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, Manns MP, Gossler A, Wilkens L, Plentz R, Zender L, Malek NP: A critical role for NOTCH signaling in the formation of cholangiocellular carcinomas. Cancer Cell 2013; 23: 784-795.
37. Hofmann JJ, Zovein AC, Koh H, Radtke F, Weinmaster G, Iruela-Arispe ML: Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: Insights into Alagille syndrome. Development 2010; 137: 4061-4072.
38. Ishimura N, Bronk SF, Gores GJ: Inducible nitric oxide synthase up-regulates NOTCH-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 2005; 128: 1354-1368.
39. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nature Reviews Cancer 2006; 6: 392-401.
40. Sirica AE: The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2012; 9: 44-54.
41. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM: Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013; 3: 636-647.
42. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, Kosuge A, Shibata T: FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2013, Epub ahead of print.
43. Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, Werneburg NW, Gustafson MP, Dietz AB, Roberts LR, Sirica AE, Gores GJ: Therapeutic effects of deleting cancer- associated fibroblasts in cholangiocarcinoma. Cancer Res 2013; 73: 897-907.
44. Razumilava N, Gradilone SA, Smoot RL, Mertens JC, Bronk SF, Sirica AE, Gores GJ: Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol 2014;60:599-605.